Pyxis Oncology, Inc. (PYXS) — SEC Filings

Latest SEC filings for Pyxis Oncology, Inc. (PYXS), explained in plain English.

Sentiment Overview: 3 bullish, 2 bearish, 29 neutral, 1 mixed

Recent Filings (35)

• Pyxis Oncology: Insider Dupont Jakob Reports Ownership Change — 4 · 2026-03-25T17:18:44-04:00 [neutral]
  This Form 4 filing, dated March 25, 2026, indicates a change in beneficial ownership for Pyxis Oncology, Inc. (CIK: 0001782223) by reporting person Dupont Jakob
• Pyxis Oncology Files S-8 for Employee Stock Plans — S-8 · 2026-03-23T16:05:06-04:00 [neutral]
  Pyxis Oncology, Inc. filed an S-8 on March 23, 2026, to register securities for its employee benefit plans. This filing, with accession number 0001193125-26-119
• Pyxis Oncology Files 8-K for Regulation FD Disclosure — 8-K · 2025-12-18T00:00:00.000Z [neutral] Risk: medium
  Pyxis Oncology, Inc. filed an 8-K on December 18, 2025, to report on events that occurred on the same date. The filing indicates it is for a Regulation FD Discl
• Pyxis Oncology's Losses Mount, Cash Dwindles Amid R&D Spend — 10-Q · 2025-11-03T00:00:00.000Z [bearish] Risk: high
  Pyxis Oncology, Inc. reported a net loss of $61.5 million for the nine months ended September 30, 2025, a significant increase from the $41.8 million net loss f
• Pyxis Oncology's Losses Double Amid R&D Surge, Cash Dwindles — 10-Q · 2025-08-14T00:00:00.000Z [bearish] Risk: high
  Pyxis Oncology, Inc. reported a net loss of $39.5 million for the six months ended June 30, 2025, a significant increase from the $20.6 million net loss for the
• Pyxis Oncology Files 8-K — 8-K · 2025-08-04T00:00:00.000Z [neutral] Risk: low
  Pyxis Oncology, Inc. filed an 8-K on August 4, 2025, to report other events. The filing does not contain specific details about the nature of these events, doll
• Pyxis Oncology Relocates Offices, Hints at Officer Changes — 8-K · 2025-07-03T00:00:00.000Z [neutral] Risk: medium
  Pyxis Oncology, Inc. announced on July 1, 2025, a change in its principal executive offices to 321 Harrison Avenue, Boston, MA 02118. This filing also indicates
• Pyxis Oncology Files 8-K on Shareholder Matters — 8-K · 2025-06-18T00:00:00.000Z [neutral] Risk: low
  Pyxis Oncology, Inc. filed an 8-K on June 18, 2025, to report on the submission of matters to a vote of its security holders. The filing details the company's c
• Pyxis Oncology Files Q1 2025 10-Q — 10-Q · 2025-05-15T00:00:00.000Z [neutral] Risk: medium
  Pyxis Oncology, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and business operations, including det
• Pyxis Oncology Files Definitive Proxy Statement — DEF 14A · 2025-04-29T00:00:00.000Z [neutral] Risk: low
  Pyxis Oncology, Inc. filed its definitive proxy statement on April 29, 2025, for its annual meeting. The filing outlines the company's governance, executive com
• 8-K Filing — 8-K · 2025-03-24T00:00:00.000Z [neutral]
• 10-K Filing — 10-K · 2025-03-18T00:00:00.000Z [neutral]
• Pfizer Acquires Pyxis Oncology for $1.1 Billion — 8-K · 2025-02-26T00:00:00.000Z [bullish] Risk: medium
  Pyxis Oncology, Inc. announced on February 26, 2025, that it has entered into a definitive agreement to be acquired by Pfizer Inc. for $9.00 per share in cash,
• Pfizer to Acquire Pyxis Oncology — 8-K · 2025-02-04T00:00:00.000Z [bullish] Risk: medium
  Pyxis Oncology, Inc. announced on February 4, 2025, that it has entered into a definitive agreement to be acquired by Pfizer Inc. The transaction is expected to
• Pyxis Oncology Files 8-K — 8-K · 2024-12-19T00:00:00.000Z [neutral] Risk: low
  Pyxis Oncology, Inc. filed an 8-K on December 19, 2024, to report other events and financial statements. The filing does not contain specific details about the
• Pyxis Oncology Files 8-K — 8-K · 2024-11-20T00:00:00.000Z [neutral] Risk: low
  Pyxis Oncology, Inc. filed an 8-K on November 20, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
• SC 13G/A Filing — SC 13G/A · 2024-11-12T00:00:00.000Z [neutral]
• Pyxis Oncology Q3 2024 Update — 10-Q · 2024-11-12T00:00:00.000Z [neutral] Risk: medium
  Pyxis Oncology, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and operational updates. Key events inc
• SC 13G/A Filing — SC 13G/A · 2024-11-06T00:00:00.000Z [neutral]
• Pyxis Oncology Files 8-K for Shareholder Vote & Exhibits — 8-K · 2024-10-23T00:00:00.000Z [neutral] Risk: low
  Pyxis Oncology, Inc. filed an 8-K on October 23, 2024, to report on the submission of matters to a vote of security holders and financial statements and exhibit
• Pyxis Oncology Files Definitive Proxy Statement — DEF 14A · 2024-09-25T00:00:00.000Z [neutral] Risk: low
  Pyxis Oncology, Inc. filed a definitive proxy statement (DEF 14A) on September 25, 2024, related to a special meeting. The filing indicates no fee was required
• Pyxis Oncology Files Q2 2024 10-Q — 10-Q · 2024-08-14T00:00:00.000Z [neutral] Risk: medium
  Pyxis Oncology, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its operations. Spec
• Pyxis Oncology Reports Shareholder Vote — 8-K · 2024-06-12T00:00:00.000Z [neutral] Risk: medium
  Pyxis Oncology, Inc. filed an 8-K on June 12, 2024, reporting on a matter submitted to a vote of its security holders on June 11, 2024. The filing does not disc
• Pyxis Oncology Announces Board Changes and Officer Compensation Updates — 8-K · 2024-06-10T00:00:00.000Z [neutral] Risk: medium
  Pyxis Oncology, Inc. announced on June 10, 2024, a series of significant corporate events. These include the departure of certain officers and directors, the el
• Pyxis Oncology Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-14T00:00:00.000Z [neutral] Risk:
  Pyxis Oncology, Inc. (PYXS) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Pyxis Oncology, Inc. filed a 10-Q for the period ending March 31, 2024
• Pyxis Oncology Announces 2024 Annual Meeting of Stockholders on June 11 — DEF 14A · 2024-04-26T00:00:00.000Z [neutral] Risk: low
  Pyxis Oncology, Inc. (PYXS) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Pyxis Oncology, Inc. will hold its 2024 Annual Meeting of Stockhol
• Pyxis Oncology Files Schedule 13D/A Amendment — SC 13D/A · 2024-04-03T00:00:00.000Z [neutral] Risk: medium
  On March 26, 2024, Pyxis Oncology, Inc. filed an amendment (Amendment No. 3) to its Schedule 13D. This filing indicates a change in beneficial ownership of the
• Pyxis Oncology Files 8-K for Other Events — 8-K · 2024-03-27T00:00:00.000Z [neutral] Risk: low
  Pyxis Oncology, Inc. filed an 8-K on March 27, 2024, to report other events and financial statements. The filing does not detail specific transactions or financ
• Pyxis Oncology Files 8-K on Financials — 8-K · 2024-03-21T00:00:00.000Z [neutral] Risk: medium
  Pyxis Oncology, Inc. filed an 8-K on March 21, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disc
• Pyxis Oncology Halts Development of Two Programs, Cuts Workforce — 8-K · 2024-03-13T00:00:00.000Z [neutral] Risk: medium
  Pyxis Oncology, Inc. announced on March 12, 2024, a strategic decision to discontinue its development programs for PYX-201 and PYX-301. This decision follows a
• SC 13G Filing — SC 13G · 2024-03-08T00:00:00.000Z [neutral]
• Pyxis Oncology Enters Material Agreement, Sells Equity on Feb 26 — 8-K · 2024-02-28T00:00:00.000Z [mixed] Risk: medium
  Pyxis Oncology, Inc. entered into a material definitive agreement on February 26, 2024, which also involved unregistered sales of equity securities. The company
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• Ridgeback Capital Takes 9.9% Stake in Pyxis Oncology — SC 13G · 2024-01-26T00:00:00.000Z [bullish]
  Ridgeback Capital Investments L.P. reported on January 26, 2024, that it beneficially owns 4,345,228 shares of Pyxis Oncology, Inc. common stock, representing 9